Results 131 to 140 of about 78,778 (305)

A Case of Systemic Amyloidosis Diagnosed After Excision of a Cutaneous Tumour of the Buttocks

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT A 72‐year‐old Japanese man was referred to our hospital with two tumours on the buttocks. Two solitary, 2.5 × 1.5 cm‐sized, dark brown, well‐demarcated elevated plaques were observed, one on each side of the gluteal cleft, and dermoscopic examination showed comedo‐like openings, multiple milia‐like cysts, and a cerebriform pattern with ...
Tomomichi Shimizu   +9 more
wiley   +1 more source

Evaluation of CD38 and CD138 as Diagnostic Markers in the Pathologic Diagnosis of Chronic Endometritis

open access: yesClinical and Experimental Obstetrics & Gynecology
Background:Chronic endometritis (CE) is a prevalent gynecological disorder and a major cause of female infertility. However, clearly defined clinical or histopathological diagnostic criteria for CE are still lacking.
Xishan Chen   +6 more
doaj   +1 more source

Evidence for targeting of CD38 mRNA by the post-transcriptional regulator protein ZFP36L1

open access: yes, 2015
Introduction: The ZFP36 family of post-transcriptional regulator proteins include ZFP36, ZFP36L1 and ZFP36L2. These proteins are post-transcriptional regulators of gene expression that bind to adenine uridine rich elements (AREs) in the 3’ untranslated ...
Murphy, J.J.
core  

Olaparib Blocks Oxidative Stress‐Dependent NLRP3 Inflammasome in Pediatric Acute Lung Injury by Metabolic Reprogramming via AMPK‐Driven Autophagic Flux

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Pediatric acute lung injury (ALI) is a life‐threatening syndrome defined by dysregulated pulmonary inflammation and impaired alveolar gas exchange, with limited therapeutic interventions. This study aims to evaluate the therapeutic efficacy and mechanistic basis of Olaparib, a clinically approved PARP inhibitor, using in vitro and in vivo ...
Fen Gong   +5 more
wiley   +1 more source

Interference and treatment strategy of a novel anti-CD38 antibody—mezagitamab in pre-transfusion test

open access: yesZhongguo shuxue zazhi
[Objective] To investigate the specific interference of the novel anti-CD38 antibody mezagitamab in pretransfusion testing, establish an immunomagnetic bead pre-treatment method to eliminate it, and evaluate its impact on other blood group systems and ...
WEI Hua   +4 more
doaj   +1 more source

CD38 as a prognostic marker in CLL

open access: yesHematology, 2005
Cell-surface expression of CD38 in CLL has been recognised recently as a marker of progressive disease and poor outcome. In contrast to traditional staging systems, CD38 is able to identify progressive cases at an early stage. Measurement of CD38, in conjunction with other novel prognostic factors such as p53 and ZAP-70 helps to identify patients who ...
openaire   +2 more sources

Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells

open access: yes, 2018
Chimeric antigen receptor T cells (CAR-Ts) are a promising strategy for the treatment of many cancers, including multiple myeloma (MM), a hematological malignancy characterized by the high expression of CD38.
Qiong Li Zhang   +19 more
core   +1 more source

Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research

open access: yesMass Spectrometry Reviews, EarlyView.
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik   +3 more
wiley   +1 more source

Tp53 Genetic Mutations in Chronic Lymphocytic Leukemia Patients in Iraq

open access: yesJournal of Applied Hematology
Background: Chronic lymphocytic leukemia (CLL) is a malignant clonal proliferative condition of mature CD5+ B cells, with a 4.2/100,000 annual incidence rate and the median age at diagnosis is 72 years.
Kareem Abed Mobashr   +2 more
doaj   +1 more source

Fetal Cells in Maternal Blood for Noninvasive Prenatal Testing—Is it Still a Distant Star?

open access: yesPrenatal Diagnosis, EarlyView.
ABSTRACT Accurate and safe prenatal diagnosis of severe genetic disorders remains challenging despite advances in genomic technologies and increased use of cell‐free noninvasive prenatal testing (cfNIPT). Currently, approximately half of pathogenic copy number variants (pCNVs) and most monogenic disorders are identified only postnatally.
Ripudaman Singh   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy